Return to Clinical Trials Search Results

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

The purpose of this study is to assess correlations between expression of blood serum biomarkers and cognitive impairment (CI) in patients with colorectal cancer throughout and following chemotherapy treatment. Our primary goal is to establish a panel of biomarkers that predict CI that can be evaluated in larger studies in the future for early interventions such as cognitive rehabilitation or further evaluation as potential pharmaceutical targets. Our hypothesis is that there is an association between CI and changes in blood serum biomarkers throughout and following chemotherapy treatment. Study objectives include: o Quantifying CI using the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)1,2 perceived cognitive impairment subscale at various time points in patients with colorectal cancer throughout and following chemotherapy treatment. o Assessing correlations between CI and biomarkers in the blood (soluble proteins or blood mononuclear cells that are cryopreserved for later examinations) of patients throughout and following chemotherapy treatment

Recruitment Status

Current Studies